CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
52 hedge funds and large institutions have $149M invested in CERo Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
16% more funds holding
Funds holding: 45 → 52 (+7)
9% more capital invested
Capital invested by funds: $137M → $149M (+$11.8M)
0% more ownership
Funds ownership: 0.04% → 0.04% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$5.01M |
| 2 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$4.63M |
| 3 |
SCM
Saba Capital Management
New York
|
+$3.99M |
| 4 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$3.52M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$2.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$12.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.5M |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$3.81M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$2.6M |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$152K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
UBS Group
Zurich,
Switzerland
| $6K | – | – | – |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $2K | – | – | – |
|
|
MF
53
Magnetar Financial
Evanston,
Illinois
| $412 | +$421K | +21 | New |
|
|
SCM
54
Segantii Capital Management
Hong Kong
| $100 | – | – | – |
|
|
BCM
55
Beryl Capital Management
Redondo Beach,
California
| – | -$12.3M | -615 | Closed |
|
|
56
Citadel Advisors
Miami,
Florida
| – | -$7.5M | -375 | Closed |
|
|
SCC
57
Spring Creek Capital
Wichita,
Kansas
| – | -$1M | -50 | Closed |
|
|
OMC
58
Old Mission Capital
Chicago,
Illinois
| – | -$152K | -8 | Closed |
|
|
AA
59
Ancora Advisors
Cleveland,
Ohio
| – | -$50K | -3 | Closed |
|
CERO Hedge Fund Activity: Q2 2022 in Review
52 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q2 2022, worth a combined $149M — up 8.6% from $137M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CERO positions and 5 closed out — a net gain of 7 holders — while 12 added to existing stakes and 4 trimmed.
The largest buyer was HGC Investment Management, adding an estimated $5.01M. The largest seller was Beryl Capital Management, exiting entirely with an estimated $12.3M sold.
- 52 institutional investors held CERo Therapeutics (CERO) as of Q2 2022, up from 45 in Q1 2022.
- Funds reported $149M of CERo Therapeutics stock for Q2 2022, up 8.6% quarter-over-quarter.
- 12 funds opened new CERo Therapeutics positions in Q2 2022 and 5 closed out, a net change of +7 holders.
- The largest CERo Therapeutics buyer in Q2 2022 was HGC Investment Management, an estimated $5.01M added.
- The largest CERo Therapeutics seller in Q2 2022 was Beryl Capital Management, an estimated $12.3M sold.
Based on aggregated 13F filings for Q2 2022.